SeeThruEquity Issues Update on DelMar Pharmaceuticals Highlighting Partnership with MD Anderson

SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, announced that it has issued an update note on DelMar Pharmaceuticals (OTCQX:DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.
SeeThruEquity CEO, Ajay Tandon, stated:

Since our last update on the company, Delmar has announced a major new collaborative partnership with the University of Texas MD Anderson Cancer Center. In our view, the announcement underscores the progress Delmar has made in showing that VAL-083 has potential to significantly improve the standard of care for GBM, and the management has stated that it believes the small molecule may offer measurable “advantages over currently available chemotherapies in a number of tumor types.
In the announcement, Delmar indicated that MD Anderson had agreed to “extend and accelerate” the clinical development of VAL-083 for glioblastoma multiforme patients following first recurrence of the disease. As part of the collaboration, MD Anderson has agreed to initiate a new Phase II clinical study with VAL-083 at first recurrence/progression, prior to Avastin® exposure. Eligible patients will have recurrent GBM characterized by a high expression of MGMT, the DNA repair enzyme implicated in drug-resistance and poor patient outcomes following current front-line chemotherapy.We are reiterating our price target of $5.75 per share.

Connect with DelMar Pharmaceuticals (OTCQX:DMPI) to receive an Investor Presentation.